Pulmonary Arterial Hypertension (PAH) Pathophysiology: Treatment Pathways 

In this program for healthcare professionals treating patients with Pulmonary Arterial Hypertension (WHO Group 1 PAH), you will learn how PAH negatively impacts the small pulmonary arteries, ultimately leading to reduced cardiac output and right heart failure. Medications are approved to treat 3 of the PAH pathways. Appropriate and timely use of a combination of PAH medications to improve risk status has been shown to extend patient’s 5-year survival.
This video uses medical animation to visually depict the impact of PAH on lung vessels and explains the mechanistic activity for each class of medication.
Content in the video includes:
• Pathophysiology of PAH
• Primary Disease Pathways
• Actions to Impact PAH Outcomes